Global, Regional, and National Burden of Chronic Hepatitis B-Related Cirrhosis From 1990 to 2021 and Projections to 2050: A Finding From the Global Burden of Disease Study 2021.
[INTRODUCTION] Chronic hepatitis B (CHB) is a widespread liver infection caused by hepatitis B virus, affecting 296 million people globally.
APA
Sun J, Guo J (2025). Global, Regional, and National Burden of Chronic Hepatitis B-Related Cirrhosis From 1990 to 2021 and Projections to 2050: A Finding From the Global Burden of Disease Study 2021.. Clinical and translational gastroenterology, 16(10), e00890. https://doi.org/10.14309/ctg.0000000000000890
MLA
Sun J, et al.. "Global, Regional, and National Burden of Chronic Hepatitis B-Related Cirrhosis From 1990 to 2021 and Projections to 2050: A Finding From the Global Burden of Disease Study 2021.." Clinical and translational gastroenterology, vol. 16, no. 10, 2025, pp. e00890.
PMID
40643591
Abstract
[INTRODUCTION] Chronic hepatitis B (CHB) is a widespread liver infection caused by hepatitis B virus, affecting 296 million people globally. The disease often progresses to severe conditions such as cirrhosis, hepatocellular carcinoma, and liver failure. The aim of this study was to evaluate the global, regional, and national burden of CHB-related cirrhosis from 1990 to 2021 and projected the disease development from 2022 to 2050.
[METHODS] In this study, data from the Global Burden of Disease 2021 database were used to analyze the global burden of CHB-related cirrhosis. Metrics such as incidence, prevalence, deaths, disability-adjusted life-years (DALYs), years lived with disability, and years of life lost were examined. Descriptive analysis explored the burden distribution by sex, age, Sociodemographic Index levels, and country in 1990 and 2021. Trend analysis used estimated annual percentage change to assess changes in age-standardized rates over time. The Autoregressive Integrated Moving Average model and the exponential smoothing model were applied to predict future trends.
[RESULTS] In 2021, CHB-related cirrhosis caused 4.8 million incident cases, 432,000 deaths, and 13.9 million DALYs globally, with decreasing trends in age-standardized incidence rate, age-standardized mortality rate, and age-standardized DALYs rate since 1990. Men exhibited higher burdens than women. Age-specific analysis revealed the highest age-standardized incidence rate in those aged younger than 5 years and the highest age-standardized mortality rate in the 85-89 years age group. Regionally, the greatest burden was observed in low Sociodemographic Index areas, with Sierra Leone and Egypt showing the highest rates. Projections indicate stable mortality but declining incidence and slightly increasing DALYs globally by 2050, with minor sex-specific variations.
[DISCUSSION] The 2021 Global Burden of Disease Study highlights progress in reducing CHB-related cirrhosis. Targeted efforts and lessons from successful interventions are essential to further alleviate this burden and improve outcomes worldwide.
[METHODS] In this study, data from the Global Burden of Disease 2021 database were used to analyze the global burden of CHB-related cirrhosis. Metrics such as incidence, prevalence, deaths, disability-adjusted life-years (DALYs), years lived with disability, and years of life lost were examined. Descriptive analysis explored the burden distribution by sex, age, Sociodemographic Index levels, and country in 1990 and 2021. Trend analysis used estimated annual percentage change to assess changes in age-standardized rates over time. The Autoregressive Integrated Moving Average model and the exponential smoothing model were applied to predict future trends.
[RESULTS] In 2021, CHB-related cirrhosis caused 4.8 million incident cases, 432,000 deaths, and 13.9 million DALYs globally, with decreasing trends in age-standardized incidence rate, age-standardized mortality rate, and age-standardized DALYs rate since 1990. Men exhibited higher burdens than women. Age-specific analysis revealed the highest age-standardized incidence rate in those aged younger than 5 years and the highest age-standardized mortality rate in the 85-89 years age group. Regionally, the greatest burden was observed in low Sociodemographic Index areas, with Sierra Leone and Egypt showing the highest rates. Projections indicate stable mortality but declining incidence and slightly increasing DALYs globally by 2050, with minor sex-specific variations.
[DISCUSSION] The 2021 Global Burden of Disease Study highlights progress in reducing CHB-related cirrhosis. Targeted efforts and lessons from successful interventions are essential to further alleviate this burden and improve outcomes worldwide.
MeSH Terms
Humans; Hepatitis B, Chronic; Liver Cirrhosis; Male; Female; Global Burden of Disease; Middle Aged; Adult; Incidence; Disability-Adjusted Life Years; Aged; Young Adult; Prevalence; Adolescent; Global Health; Aged, 80 and over; Child, Preschool; Quality-Adjusted Life Years; Child
같은 제1저자의 인용 많은 논문 (5)
- Dietary Urolithin B Suppresses Lung Tumorigenesis Correlating with Autophagy Induction and Gut Microbiota Remodeling.
- Interplay between natural killer cells and ferroptosis: novel insights in tumor immunity and therapeutic potential.
- Traditional Mongolian medicine Batri-7 exhibits chemopreventive activity in colitis-associated colorectal cancer through microbiota modulation and NLRP3 inflammasome targeting.
- The predictive value of the lymphocyte-C-reactive protein ratio for early recurrence in MVI positive HCC patients who underwent postoperative adjuvant transcatheter arterial chemoembolization.
- Aspirin inhibits proliferation and promotes apoptosis of hepatocellular carcinoma cells via Wnt/β-catenin signaling pathway.